Arbutus to Report First Quarter 2021 Financial Results and Provide Corporate Update
WARMINSTER, Pa., April 28, 2021 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on developing a cure for people with chronic hepatitis B virus (HBV) infection, as well as therapies to treat coronaviruses (including COVID-19), today announced that it has scheduled its first quarter 2021 financial results and corporate update for Wednesday, May 5, 2021. The schedule for the press release and conference call/webcast are as follows:
| • | 1Q/2021 Press Release: | Wednesday, May 5, 2021 at 7:30 a.m. ET |
| • | 1Q/2021 Conference Call/Webcast: | Wednesday, May 5, 2021 at 8:45 a.m. ET |
| • | Domestic Dial-In Number: | (866) 393-1607 |
| • | International Dial-In Number: | (914) 495-8556 |
| • | Conference ID Number: | 4445858 |
A live webcast of the conference call can be accessed through the Investors section of Arbutus' website at or directly at .
An archived webcast will be available on the Arbutus website after the event. Alternatively, you may access a replay of the conference call by calling (855) 859-2056 or (404) 537-3406, and reference conference ID: 4445858.
About Arbutus
Arbutus Biopharma Corporation is a publicly traded (Nasdaq: ABUS) biopharmaceutical company dedicated to discovering, developing and commercializing a cure for people with chronic hepatitis B virus (HBV) infection. The Company is advancing multiple drug product candidates that may be combined into a potentially curative regimen for chronic HBV infection. Arbutus has also initiated a drug discovery and development effort for treating coronaviruses (including COVID-19). For more information, visit .
Contact Information
Investors and Media
William H. Collier
President and CEO
Phone: 267-469-0914
Email:
Pam Murphy
Investor Relations Consultant
Phone: 267-469-0914
Email:
